Kura Oncology (NASDAQ:KURA) Rating Lowered to Neutral at BTIG Research

BTIG Research lowered shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a neutral rating in a research report released on Thursday morning, MarketBeat Ratings reports.

KURA has been the subject of several other reports. HC Wainwright raised their target price on shares of Kura Oncology from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. UBS Group started coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Jefferies Financial Group lowered their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Finally, Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Performance

NASDAQ KURA opened at $8.82 on Thursday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average is $8.79 and its two-hundred day moving average is $15.11. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period in the previous year, the company earned ($0.50) EPS. On average, analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Activity

In related news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,255 shares of company stock valued at $100,739. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Hedge funds have recently modified their holdings of the business. nVerses Capital LLC acquired a new position in Kura Oncology during the 3rd quarter valued at $25,000. E Fund Management Co. Ltd. bought a new position in shares of Kura Oncology during the 4th quarter worth about $90,000. China Universal Asset Management Co. Ltd. raised its position in shares of Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after buying an additional 1,750 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology in the third quarter valued at about $146,000. Finally, US Bancorp DE grew its position in Kura Oncology by 184.5% during the fourth quarter. US Bancorp DE now owns 22,104 shares of the company’s stock worth $193,000 after buying an additional 14,335 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.